Rhenman & Partners Asset Management AB Has $6.16 Million Position in Krystal Biotech, Inc. $KRYS

Rhenman & Partners Asset Management AB boosted its position in Krystal Biotech, Inc. (NASDAQ:KRYS) by 112.8% in the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 25,000 shares of the company’s stock after purchasing an additional 13,250 shares during the period. Rhenman & Partners Asset Management AB’s holdings in Krystal Biotech were worth $6,164,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also bought and sold shares of KRYS. Royal Bank of Canada increased its holdings in Krystal Biotech by 145.2% in the 1st quarter. Royal Bank of Canada now owns 1,628 shares of the company’s stock worth $294,000 after purchasing an additional 964 shares in the last quarter. AQR Capital Management LLC increased its holdings in Krystal Biotech by 29.9% in the 1st quarter. AQR Capital Management LLC now owns 12,131 shares of the company’s stock worth $2,187,000 after purchasing an additional 2,792 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its holdings in Krystal Biotech by 4.5% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 15,893 shares of the company’s stock worth $2,870,000 after purchasing an additional 688 shares in the last quarter. Empowered Funds LLC acquired a new position in Krystal Biotech in the 1st quarter worth about $218,000. Finally, Cetera Investment Advisers increased its holdings in Krystal Biotech by 107.9% in the 2nd quarter. Cetera Investment Advisers now owns 4,344 shares of the company’s stock worth $597,000 after purchasing an additional 2,255 shares in the last quarter. Institutional investors and hedge funds own 86.29% of the company’s stock.

Insider Activity at Krystal Biotech

In related news, insider Suma Krishnan sold 25,000 shares of the firm’s stock in a transaction that occurred on Thursday, June 4th. The stock was sold at an average price of $308.11, for a total transaction of $7,702,750.00. Following the completion of the sale, the insider owned 1,378,155 shares of the company’s stock, valued at $424,623,337.05. This trade represents a 1.78% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP John Charles Thomas sold 642 shares of the firm’s stock in a transaction that occurred on Tuesday, May 26th. The stock was sold at an average price of $302.03, for a total value of $193,903.26. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Company insiders own 13.10% of the company’s stock.

Analyst Upgrades and Downgrades

KRYS has been the subject of a number of recent research reports. Wall Street Zen raised Krystal Biotech from a “hold” rating to a “buy” rating in a report on Saturday, May 9th. Wolfe Research initiated coverage on Krystal Biotech in a report on Friday, March 27th. They issued a “peer perform” rating for the company. Chardan Capital upped their target price on Krystal Biotech from $220.00 to $323.00 and gave the stock a “buy” rating in a report on Wednesday, February 18th. HC Wainwright reaffirmed a “buy” rating and issued a $310.00 target price on shares of Krystal Biotech in a report on Monday, June 1st. Finally, Evercore reaffirmed an “outperform” rating and issued a $300.00 target price on shares of Krystal Biotech in a report on Tuesday, May 5th. Ten equities research analysts have rated the stock with a Buy rating and two have issued a Hold rating to the company. Based on data from MarketBeat.com, Krystal Biotech currently has an average rating of “Moderate Buy” and an average target price of $324.11.

Krystal Biotech Price Performance

NASDAQ KRYS opened at $317.97 on Friday. The business has a 50 day simple moving average of $288.44 and a 200 day simple moving average of $267.89. Krystal Biotech, Inc. has a one year low of $127.99 and a one year high of $331.49. The stock has a market capitalization of $9.37 billion, a P/E ratio of 42.51 and a beta of 0.53.

Krystal Biotech (NASDAQ:KRYS) last released its earnings results on Monday, May 4th. The company reported $1.83 EPS for the quarter, topping the consensus estimate of $1.45 by $0.38. Krystal Biotech had a return on equity of 19.25% and a net margin of 53.92%.The business had revenue of $116.36 million during the quarter, compared to analysts’ expectations of $112.11 million. Equities analysts expect that Krystal Biotech, Inc. will post 7.83 earnings per share for the current year.

Krystal Biotech Company Profile

Krystal Biotech, Inc is a clinical-stage biotechnology company focused on developing gene therapies for rare dermatological diseases. Headquartered in Pittsburgh, Pennsylvania, the company applies proprietary viral vector delivery technology to enable topical administration of corrective genes directly to the skin. By targeting the underlying genetic causes of inherited skin disorders, Krystal Biotech seeks to address areas of high unmet medical need with potentially transformative treatments.

The company’s lead product candidate, KB103, is designed to deliver a functional COL7A1 gene to patients with dystrophic epidermolysis bullosa (DEB), a severe and often debilitating blistering condition.